General AML

Final analysis of the phase III ALFA-0701 study of gemtuzumab ozogamicin in de novo acute myeloid leukemia

Cynthia Umukoro , Aug 6, 2018

General AML

Results from the APL 2006 trial of arsenic trioxide in patients with acute promyelocytic leukemia

Cynthia Umukoro , Aug 3, 2018

FLT3

FDA grants Breakthrough Therapy Designation to quizartinib for relapsed/refractory FLT3-ITD acute myeloid leukemia

Cynthia Umukoro , Aug 2, 2018

General AML

EMA COMP grants positive opinion recommending PCM-075 for Orphan Drug Designation for the treatment of acute myeloid leukemia

Cynthia Umukoro , Aug 2, 2018

General AML

Phase Ib/IIa study of dasatinib in adult patients with newly diagnosed core binding factor acute myeloid leukemia 

Cynthia Umukoro , Aug 1, 2018

FLT3

Sorafenib in combination with azacitidine in older patients with FLT3-ITD mutated acute myeloid leukemia

Cynthia Umukoro , Jul 31, 2018

FLT3

Randomized phase IIb study of two doses of quizartinib in patients with relapsed or refractory acute myeloid leukemia

Cynthia Umukoro , Jul 26, 2018

General AML

Phase III randomized study of CPX-351 liposome for injection in older patients with newly diagnosed secondary acute myeloid…

Cynthia Umukoro , Jul 24, 2018

IDH1/2

FDA grants Tibsovo (ivosidenib) approval for the treatment of patients with relapsed/refractory acute myeloid leukemia with IDH1…

Cynthia Umukoro , Jul 23, 2018

General AML

EHA 2018 | Panobinostat, decitabine and donor lymphocyte infusion post-allogeneic transplantation in newly diagnosed poor-risk…

Cynthia Umukoro Gary Nolan , Jul 20, 2018